versal influenza immunization on respiratory antibiotic prescriptions.
Methods. We used an ecological study design of pre-and postintervention with concurrent controls. Ethics approval was obtained from the Sunnybrook Health Sciences Centre Research Ethics Board, Toronto, Canada.
Vaccination rate data were obtained from the 1996-1997 cycle of the National Population Health Survey and the [2000] [2001] 2003 , and 2005 cycles of the Canadian Community Health Survey, both conducted by Statistics Canada [9, 10] .
We obtained prescription data from the Canadian CompuScript Audit of Intercontinental Marketing Services Health Canada, which tracks numbers of prescriptions filled at a representative sample of retail pharmacies across Canada but does not contain any data on patient characteristics [11] . We included prescriptions filled for antibiotic classes typically used to treat outpatient respiratory infections (penicillins, cephalosporins, broad-spectrum macrolides, and quinolones) from August 1997 through July 2007.
Weekly reports of test results positive for influenza A, influenza B, and respiratory syncytial virus submitted by a network of sentinel laboratories to the Public Health Agency of Canada were aggregated to generate monthly percentages of test results positive for each province. We combined the 4 Atlantic provinces because of the small numbers of specimens. Using a subset of subtyped specimens, we identified the annual proportion of isolates characterized as influenza A(H3N2), because influenza A(H3N2)-predominant seasons are generally more severe than are influenza A(H1N1)-and/or influenza B-predominant seasons [12] . Using an additional subset of strain-characterized specimens, we determined the annual percentage of circulating strains that did not match those in the season's vaccine.
Periods of peak influenza activity were defined for each province as all periods when the monthly percentage of test results positive for influenza exceeded 7% (mean duration of influenza season, 3 months).
To estimate influenza-associated antibiotic prescriptions, we generated an expected baseline using province-specific Poisson regression models that controlled for influenza A, influenza B, and respiratory syncytial virus activity, influenza A(H3N2) predominance, vaccine mismatch, time trends, and seasonality (Appendix), and we set the influenza-related variables to zero [13] . Numbers of influenza-associated antibiotic prescriptions were computed as the difference between observed events and expected baseline events during periods of peak influenza activity (Fig 1) . These monthly estimates were aggregated to pro- duce annual estimates. Postintervention versus preintervention relative rates (RRs) of influenza-associated events for Ontario and for other provinces combined were computed by dividing postintervention rates by preintervention rates. The RRs were compared using the z test and were presented as a ratio.
We performed several sensitivity analyses to test the robustness of the findings. To test consistency, we compared RRs for Ontario with those for each province separately, set the threshold for defining periods of peak influenza activity to 5% and 10%, started the study period with the 1994-1995 season (excluding Quebec and Atlantic provinces because of unavailability of suitable viral surveillance data), and restricted the analysis to influenza A(H3N2)-predominant seasons (150% of isolates). To elicit effect amplification, we excluded seasons with poor vaccine match (150% of circulating strains mismatched to vaccine strains). As tests of specificity, we computed RRs for observed respiratory antibiotics prescribed during July (a month with no influenza activity; therefore, no influenza-associated events were expected) and for the nonrespiratory antibiotics trimethoprim and tetracyclines prescribed during February (a month that always had high influenza activity). To explore the existence of a dose-response relationship between temporal changes in vaccine uptake and prescription rates, we regressed province-specific vaccination rate change by RR, weighting by the inverse of the variance of the RR estimate.
Analyses were performed using SAS, version 9.1 (SAS Institute). All statistical tests were 2-sided, and P values of !.05 were considered statistically significant. Results. From 1996-1997 to post-2000, overall vaccine uptake increased from 18% to 38% in Ontario, compared with an increase from 13% to 24% in other provinces (9% incremental increase in Ontario). For those aged !65 years, vaccine uptake increased from 12% to 32% in Ontario, compared with an increase from 8% to 22% in other provinces (10% incremental increase). For those aged у65 years, vaccine uptake increased from 60% to 75% in Ontario, compared with an increase from 46% to 64% in other provinces (Ϫ3% incremental increase). Ontario maintained higher uptake rates throughout the study period.
Rates of respiratory antibiotic prescriptions generally decreased across Canada after 2000, with decreases for penicillins and cephalosporins and increases for quinolones (Table 1 ). Monthly prescription rates over the study period for Ontario and other provinces combined exhibited seasonal trends, with spikes during periods of influenza activity, and a slight overall downward trend (Fig 2) .
After UIIP introduction, rates of influenza-associated antibiotic prescriptions decreased from 17.9 to 6.4 per 1000 people in Ontario (RR, 0.36; 95% CI, 0.26-0.49), compared with a decrease from 8.3 to 8.2 per 1000 people in other provinces (RR, 0.99; 95% CI, 0.86-1.14) (ratio of RRs, 0.36; ) P ! .001 (Table 2 ). This 64% relative reduction translates to ∼144,000 In sensitivity analyses, comparisons with each province individually and varying the threshold for defining the periods of peak influenza activity produced results that were generally similar to those of the primary analysis ( Table 2) . The difference in RRs between Ontario and other provinces decreased slightly when the study period started with the 1994-1995 season and when the analysis was restricted to influenza A(H3N2)-predominant seasons. The difference was amplified when mismatched seasons post-UIIP were excluded. The differences in RRs using respiratory antibiotics prescribed during the summer or nonrespiratory antibiotic prescribed during February were either far less pronounced than in the primary analysis or were in the opposite direction. We observed a dose-response relationship between province-specific RRs and vaccination rate changes (slope, Ϫ0.05; ; ) (Fig 3) .
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P p .002 R p 0.87 Discussion. Universal influenza immunization in Ontario was associated with a 64% larger decrease in influenza-associated respiratory antibiotic prescriptions-an incremental decrease of ∼10 per 1000 population-than in other provinces that maintained targeted programs.
The plausibility of our finding is supported by several previous studies. One study found that for every 100 children, an annual mean of 3-9 courses of antibiotics are attributable to influenza [7] . Antibiotics are less likely to be prescribed to vaccinated healthy working adults [8] and household contacts of vaccinated children who attend day care [14] . Antibiotics are frequently prescribed for acute otitis media, a condition that influenza may precipitate, and influenza vaccination has been demonstrated to reduce acute otitis media incidence by 30%-36% [15] [16] [17] . Prophylaxis and treatment of influenza virus infection using neuraminidase inhibitors have also been shown to decrease antibiotic prescriptions, further supporting the link between influenza virus infection and antibiotic use [18, 19] .
The results are also congruent with previous work evaluating the impact of Ontario's UIIP. Program introduction was associated with 39%, 42%, 55%, and 59% greater decreases in influenza-associated mortality, hospitalizations, emergency department use, and doctors' office visits, respectively, in Ontario, compared with in other provinces [13] .
The interprovincial variability in antibiotic prescribing observed in this study is consistent with previous work that examined provincial differences in spending on drugs [20] and is likely related to some combination of differences in provincial formularies and reimbursement policies, clinical practice patterns, and population demographics.
This study has several limitations. Lack of individual-level data necessitated an ecological study, although this design is appropriate to assess the impact of populationwide interventions, and the design is strengthened by the inclusion of other provinces as concurrent controls. Not having prescription data by age group precluded examination of age-specific temporal changes in antibiotic prescriptions in the context of age-specific vaccine uptake. Furthermore, national vaccination rate data were unavailable for children aged !12 years, an age group with high antibiotic use. The study outcome, the number of respiratory antibiotic prescriptions, comprised several broad categories of antibiotics and included a few specific antibiotics not typically used for respiratory infections (eg, the category of quinolones included ciprofloxacin). However, because their use is likely constant throughout the year, their inclusion would be accounted for in the baseline function. We were unable to include potential confounders, such as temperature, relative humidity, strain-specific influenza surveillance data, prevalence of individual comorbidities, and provincial health care system capacity.
The results of this study have public health and clinical relevance, indicating the potential for universal influenza immunization to reduce influenza-associated antibiotic utilization by 64% more than targeted immunization. Although the impact of universal influenza immunization on the incidence of antibiotic-resistant organisms remains uncertain, jurisdictions wishing to decrease antibiotic use might consider programs to increase influenza vaccination. 
